Kisolite News


President's Update - July 2020

FOR IMMEDIATE RELEASE – Chilliwack, BC, Canada – July 2, 2020

  • Commercial Research Agreement Signed
  • About Althea DRF Life Science Limited

It is my pleasure to inform you that Kisolite Corp. has signed a contract with Althea DRF Life Science to begin preclinical development of formulated derivatives KC-S and KC-L for therapeutic benefits in multiple areas by oral and topical routes.

View PDF


Spring Newsletter by Lawry Lund, President

FOR IMMEDIATE RELEASE – Chilliwack, BC, Canada – June 10, 2020

  • Research Progress
  • Corporate Developments
  • Activities underway in 2020

Dear Shareholders,

It is my pleasure to inform you on the company’s purposeful transition from academic studies to commercial research and development. Since 2012 the company has prioritized research conducted in commercial laboratories and academic institutions to identify the components and processes required to formulate the clay from Kisameet Bay into commercial active ingredients.

View PDF


President's Update by Lawry Lund, President

FOR IMMEDIATE RELEASE – Chilliwack, BC, Canada – April 15, 2020 President's Update

At the outset of 2020 the company was busy assessing and verifying research results from UBC, which had been received at the end of December, 2019. Although the science side of the business has advanced in the intervening months since then, we are now faced with restrictions and limitations due to the COVID-19 national emergency.

The shelter-in-place requirement has caused the company to substantially reduce its operations and undertake contingency planning measures.

View PDF


President's Update by Lawry Lund, President

FOR IMMEDIATE RELEASE – Chilliwack, BC, Canada – Feb 6, 2020 President's Update

At the outset of 2020 the company has been busy assessing research results from UBC and making progress towards an alignment of all researchers involved, their findings, and ongoing activity.

While research work continues the company is setting its commercialization plans in motion, and it gives me pleasure to announce two additions to our team, Dr. Michael Stocker for Business Development and Caroline Lenardon as Manager, Shareholder Relations.

View PDF


Q4 2019 Quarterly Report and Year-End Summary by Lawry Lund, President

FOR IMMEDIATE RELEASE – Chilliwack, BC, Canada – Dec 31, 2019 Q4 2019 Shareholder Update by Lawry Lund, President

Kisolite Corp has now completed its first full year of operations. This newsletter will review the past year, inform the most recent Quarter, and outline the objectives in 2020.

Q4 Activity
The objective in Q4 2019 was to connect the Science Board of Kisolite Corp with researchers at UBC, which was accomplished and leads to a broader collaboration on research results.

During the last month the company conducted its first AGM for the period from formation to the end of 2018, essentially the set-up year. The AGM was conducted with a total of 94.49% of shares voted.

View PDF


Q3 2019 Shareholder Update by Lawry Lund, President

FOR IMMEDIATE RELEASE – Chilliwack, BC, Canada – Oct 16, 2019 Q3 2019 Shareholder Update by Lawry Lund, President

Kisolite Corp reports steady progress being made over the past three months as the company continues pre-clinical work for skin health applications.

Dr. Dirk Lange states “Considerable progress has been made on the R&D front. Studies into the compositional analysis of the clay to identify antimicrobial active components are underway. Compositional analyses are being conducted in parallel with antimicrobial studies against acne causing bacteria. Furthermore, efforts are underway for development of a Protocol for an eventual clinical trial to test efficacy against acne and potential clinical trial coordination companies have been identified and contacted.”.

View PDF


Q2 2019 Shareholder Update by Lawry Lund, President

FOR IMMEDIATE RELEASE – Chilliwack, BC, Canada – July 15, 2019 Q2 2019 Shareholder Update by Lawry Lund, President

Kisolite Corp reports that a steady activity level was maintained throughout the past three months as the company pursues pre-clinical work for skin health applications.

The company is taking guidance from the Scientific Board in a pursuit to determine new products for skin health, with the first target for Acne. Progressive targets are Psoriasis and Eczema. To that end, the website of the company has been revised to more closely represent the focus of the business.

View PDF


Kisolite Shareholder Update – Interim President’s Report

Chilliwack, BC, Canada – March 13, 2019 –Kisolite Corp, the exclusive marketer of all natural “Kisolite”, is pleased to report that final terms on our first Licensing Agreement for topical, non-medicinal soap products is being prepared for signature, and expected to be announced shortly.

View PDF


Kisolite Appoints Mark Stanton to Business Advisory Group

Chilliwack, BC, Canada – December 18, 2018 – Kisolite Corp., the exclusive marketer of all natural “Kisolite”, announces the appointment of Mark Stanton to lead the Business Advisory Group for the company.

View PDF


Kisolite Appoints 3 Additional Members to its Scientific Board

Chilliwack, BC, Canada – December 2, 2018 – Kisolite Corp., the exclusive marketer of all natural “Kisolite”, announces that Dr. Neil Branda, Dr. Dirk Lange and Rowland Hanson have joined the Scientific Board of the company. 

View PDF


Roger Kuypers Joins Kisolite’s Scientific Board

Chilliwack, BC, Canada – November 6, 2018 – Kisolite Corp., the exclusive marketer of all natural “Kisolite”, announces the formation of its new Scientific Board chaired by Vancouver, BC based lawyer Roger Kuypers. 

View PDF


Kisolite Announces Exclusive Agreement with Kisameet

Chilliwack, BC, Canada – October 22, 2018 – Kisolite Corp. announces that it has executed an Assignment and Exclusive Supply Agreement with Kisameet Glacial Clay Inc. 

View PDF